Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Cited by 271 Publications

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Immunol, 2014, 15(5):439-48

PubMed: 24681565 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Gastroenterology, 2019, 156(1):187-202

PubMed: 30267710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5324

PubMed: 31757943 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz1136

PubMed: 31799598 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(5):1005-1025

PubMed: 30599067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

Br J Cancer, 2019, 121(12):1039-1049

PubMed: 31690832 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 10:409

PubMed: 30915074 ( click the link to review the publication )
Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(7):957-972

PubMed: 31025088 ( click the link to review the publication )

J Immunol, 2019, 203(12):3199-3208

PubMed: 31732526 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786

PubMed: 31694931 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Stem Cells Int, 2019, 2019:8451282

PubMed: 30992706 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2019, 22(4):317-328

PubMed: 30668714 ( click the link to review the publication )

Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Skelet Muscle, 2019, 9(1):12

PubMed: 31113472 ( click the link to review the publication )

Biomed Pharmacother, 2019, 115:108570

PubMed: 31054509 ( click the link to review the publication )

Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Cancer Biol Ther, 2019, 20(5):700-710

PubMed: 30571927 ( click the link to review the publication )

Dev Biol, 2019, 449(2):122-131

PubMed: 30826398 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):669-682

PubMed: 30849634 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(3):e0213186

PubMed: 30830950 ( click the link to review the publication )

Pain Res Manag, 2019, 2019:1648919

PubMed: 30809320 ( click the link to review the publication )

Oncotarget, 2019, 10(20):1903-1917

PubMed: 30956773 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j.jcmgh.2019.10.005

PubMed: 31654770 ( click the link to review the publication )

eNeuro, 2019, 6(1)

PubMed: 30783618 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )
Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

EMBO Rep, 2018, 19(9)

PubMed: 30021835 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Neuropsychopharmacology, 2018, 43(8):1779-1788

PubMed: 29760409 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):623

PubMed: 29795376 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1081

PubMed: 30349042 ( click the link to review the publication )

Arch Toxicol, 2018, 92(7):2227-2243

PubMed: 29845424 ( click the link to review the publication )

Basic Res Cardiol, 2018, 114(1):3

PubMed: 30446837 ( click the link to review the publication )

Oncoimmunology, 2018, 7(11):e1466018

PubMed: 30377559 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2013-2023

PubMed: 29934340 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2013-2023

PubMed: 29934340 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2018, 1864(8):2610-2622

PubMed: 29684588 ( click the link to review the publication )

Oncogenesis, 2018, 7(4):36

PubMed: 29691367 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(11)

PubMed: 30424007 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):8492

PubMed: 29855565 ( click the link to review the publication )

Sci Rep, 2018, 8(1):12886

PubMed: 30150730 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13638

PubMed: 30206377 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9391

PubMed: 29925922 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

Mol Pharmacol, 2018, 94(2):793-801

PubMed: 29880639 ( click the link to review the publication )
Biochem J, 2018, 475(24):3921-3932

PubMed: 30552170 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(1):65-75

PubMed: 29721849 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

PLoS One, 2018, 13(3):e0194661

PubMed: 29579087 ( click the link to review the publication )

J Med Virol, 2018, 90(9):1478-1485

PubMed: 29704439 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2620-2630

PubMed: 29704392 ( click the link to review the publication )

Oncol Lett, 2018, 16(2):1967-1974

PubMed: 30008890 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467324 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Cond Med, 2018, 1(2):64-72

PubMed: 30135960 ( click the link to review the publication )

Oncotarget, 2018, 9(28):19597-19612

PubMed: 29731968 ( click the link to review the publication )

Oncotarget, 2018, 9(63):32182-32190

PubMed: 30181808 ( click the link to review the publication )

Data Brief, 2018, 17:1314-1319

PubMed: 29876485 ( click the link to review the publication )

Korean J Physiol Pharmacol, 2018, 22(1):23-33

PubMed: 29302209 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2235-2248

PubMed: 28436940 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(51):E10981-E10990

PubMed: 29203668 ( click the link to review the publication )

Cell Rep, 2017, 19(4):875-889

PubMed: 28445736 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(21):3865-3880

PubMed: 28832971 ( click the link to review the publication )
J Med Chem, 2017, 60(13):5334-5348

PubMed: 28581289 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(7):858-869

PubMed: 28669525 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )

Front Immunol, 2017, 8:671

PubMed: 28659914 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(12):2689-2700

PubMed: 28802253 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2017, 6:54-65

PubMed: 28664166 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

J Virol, 2017, 91(16)

PubMed: 28566376 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12084

PubMed: 28935977 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8641

PubMed: 28819194 ( click the link to review the publication )

Mech Ageing Dev, 2017, 166:6-15

PubMed: 28843433 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 361(1):140-150

PubMed: 28174211 ( click the link to review the publication )

J Neuropathol Exp Neurol, 2017, 76(12):1000-1007

PubMed: 29136455 ( click the link to review the publication )

J Endocrinol, 2017, 233(3):369-379

PubMed: 28438776 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2017, 312(3):F502-F515

PubMed: 28052874 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Int J Mol Med, 2017, 40(3):661-672

PubMed: 28677722 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )
Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:3-10

PubMed: 27761809 ( click the link to review the publication )

Oncotarget, 2017, 8(69):114156-114172

PubMed: 29371976 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3172-3187

PubMed: 29423038 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83155-83170

PubMed: 29137331 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4079-4095

PubMed: 27863422 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:375-385

PubMed: 27761836 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Sci Rep, 2017, 589:97-106

PubMed: 28273598 ( click the link to review the publication )

Nat Microbiol, 2016, 1:16174

PubMed: 27694949 ( click the link to review the publication )

Kidney Int, 2016, 89(2):317-26

PubMed: 26509586 ( click the link to review the publication )

Cancer Res, 2016, 76(10):3067-77

PubMed: 26980768 ( click the link to review the publication )

Cell Death Differ, 2016, 23(8):1312-21

PubMed: 26915294 ( click the link to review the publication )

Sci Signal, 2016, 9(422):ra34

PubMed: 27048565 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:62

PubMed: 27231489 ( click the link to review the publication )

Oncoimmunology, 2016, 5(11):e1219008

PubMed: 27999738 ( click the link to review the publication )

Oncoimmunology, 2016, 5(6):e1164919

PubMed: 27471639 ( click the link to review the publication )

Osteoarthritis Cartilage, 2016, 24(8):1451-60

PubMed: 27072078 ( click the link to review the publication )
Mol Cancer Ther, 2016, 15(2):299-312

PubMed: 26772204 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2432-2441

PubMed: 27474150 ( click the link to review the publication )

Pharmacol Res, 2016, 103:328-39

PubMed: 26657418 ( click the link to review the publication )

Transl Psychiatry, 2016, 6(12):e974

PubMed: 27922638 ( click the link to review the publication )

Dis Model Mech, 2016, 9(5):541-52

PubMed: 26989193 ( click the link to review the publication )

J Virol, 2016, 90(20):9018-28

PubMed: 27466424 ( click the link to review the publication )

Front Cell Neurosci, 2016, 10:221

PubMed: 27729849 ( click the link to review the publication )

Front Cell Neurosci, 2016, 9:510

PubMed: 26793062 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 311(1):L124-34

PubMed: 27233998 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2016, 10.1093/ijnp/pyw035

PubMed: 27207921 ( click the link to review the publication )

Mol Brain, 2016, 9(1):79

PubMed: 27535553 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):546-57

PubMed: 27029345 ( click the link to review the publication )

BMC Cancer, 2016, 10.1186/s12885-016-2353-7

PubMed: 27188282 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Biol Chem, 2016, 397(1):75-83

PubMed: 26431101 ( click the link to review the publication )

Methods Enzymol, 2016, 573:161-81

PubMed: 27372753 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep28025

PubMed: 27320682 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7390-402

PubMed: 26862729 ( click the link to review the publication )

Gene Regul Syst Bio, 2016, 10:9-13

PubMed: 26823649 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms7537

PubMed: ( click the link to review the publication )
Nat Commun, 2015, 6:7023

PubMed: 25960197 ( click the link to review the publication )

Nat Commun, 2015, 6:6537

PubMed: 26055519 ( click the link to review the publication )

Nat Commun, 2015, 6:6537

PubMed: 26055519 ( click the link to review the publication )

Nat Commun, 2015, 6:7023

PubMed: 25960197 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(14):3230-3240

PubMed: 25813020 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Control Release, 2015, 204:20-9

PubMed: 25681050 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26701908 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

J Neurosci, 2015, 35(3):1250-9

PubMed: 25609639 ( click the link to review the publication )

Br J Cancer, 2015, 112(2):329-37

PubMed: 25514379 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: 25284154 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Toxicol Sci, 2015, 148(1):220-8

PubMed: 26251326 ( click the link to review the publication )

Sci Rep, 2015, 5:16873

PubMed: 26585834 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 10.1093/ijnp/pyv029

PubMed: 25762717 ( click the link to review the publication )
Front Neurosci, 2015, 9:319

PubMed: 26441495 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 151(2):281-94

PubMed: 25904215 ( click the link to review the publication )

Virology, 2015, 485:340-54

PubMed: 26331681 ( click the link to review the publication )

J Appl Physiol (1985), 2015, 119(4):342-51

PubMed: 26112243 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144660

PubMed: 26713848 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137699

PubMed: 26361334 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Future Virol, 2015, 10(4), 351–356

PubMed: ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25784-800

PubMed: 26329759 ( click the link to review the publication )

Sheng Li Xue Bao, 2015, 67(5):447-54

PubMed: 26490061 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25801-14

PubMed: 26317649 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Genes Dev, 2014, 28(14):1578-91

PubMed: 25030697 ( click the link to review the publication )

PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28924

PubMed: 24771510 ( click the link to review the publication )

Addict Biol, 2014, 10.1111/adb.12161.

PubMed: 25041570 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(1):32-7

PubMed: 24165483 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 7):1441-53

PubMed: 24463822 ( click the link to review the publication )

Eur J Immunol, 2014, 44(8):2478-88

PubMed: 24810486 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(3):415-27

PubMed: 24248598 ( click the link to review the publication )
Retrovirology, 2014, 11:67

PubMed: 25116364 ( click the link to review the publication )

Neuromolecular Med, 2014, 16(4):727-41

PubMed: 25063076 ( click the link to review the publication )

Pharmacological Reports, 2014, 49–55

PubMed: ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106784

PubMed: 25198282 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115401

PubMed: 25521755 ( click the link to review the publication )

Pharmacol Rep, 2014, 66(1):49-55

PubMed: 24905306 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4516-28

PubMed: 24980831 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(28):E2621-8

PubMed: 23788661 ( click the link to review the publication )

Genet Mol Biol, 2013, 36(3):299-307

PubMed: 24130434 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(1):118-27

PubMed: 23091117 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2076-86

PubMed: 23047626 ( click the link to review the publication )

J Neuroscience, 2013, 33(50):19664-76

PubMed: 24336730 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Stem Cells, 2013, 31(7):1434-45

PubMed: 23592435 ( click the link to review the publication )
Mol Cancer Ther, 2013, 12(10):2078-87

PubMed: 23939379 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Neurochem, 2013, 129(3):509-15

PubMed: 24147654 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Infect Immun, 2013, 82(2):706-19

PubMed: 24478085 ( click the link to review the publication )

Mol Reprod Dev, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )

Pediatr Nephrol, 2013, 28(10):1909-21

PubMed: 23052657 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74930

PubMed: 24058639 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Exp Hematol, 2013, 41(1):113-23.e2

PubMed: 22989761 ( click the link to review the publication )

Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(12):2600-9

PubMed: 23012246 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Immunol, 2012, 189(4):1792-9

PubMed: 22786766 ( click the link to review the publication )

Eur Neuropsychopharmacol, 2012, 22(9):651-6

PubMed: 22341945 ( click the link to review the publication )

J Am Heart Assoc, 2012, 1(3):e000901

PubMed: 23130137 ( click the link to review the publication )

J Virol, 2012, 86(6):3073-87

PubMed: 22238308 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41776

PubMed: 22848598 ( click the link to review the publication )

Biochem Biophys Res Commun, 2012, 428(1):121-6

PubMed: 23063976 ( click the link to review the publication )

Biomol Ther (Seoul), 2012, 20(1):81-8

PubMed: 24116279 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

J Thorac Oncol, 2011, 6(7):1152-61

PubMed: 21597390 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(49):19629-34

PubMed: 22106282 ( click the link to review the publication )
J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 414(1):25-30

PubMed: 21925145 ( click the link to review the publication )

J Biomed Biotechnol, 2011, 2011:371832

PubMed: 21151613 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Mol Pain, 2010, 6:51

PubMed: 20822541 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14462

PubMed: 21283510 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Targets

HDAC1 ^[2] (Cell-free assay)	HDAC3 ^[2] (Cell-free assay)
0.51 μM	1.7 μM

In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21^WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. ^[1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. ^[2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
SCC-3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjVTWM2OD1yLkC2NUDPxE1?	MWfTRW5ITVJ?
ALL-PO	MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3TcpZTUUN3ME2wMlA3OzV3IN88US=>	M{Lj[3NCVkeHUh?=
697	MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3i2NWlEPTB;MD6wPVk4PiEQvF2=	MUDTRW5ITVJ?
NCI-H748	M2\IeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LRdmlEPTB;MD6xNFM{PCEQvF2=	NGTVRnRUSU6JRWK=
NKM-1	NWrJfXZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXWx[JRnUUN3ME2wMlExQTF{IN88US=>	NVHDO2RoW0GQR1XS
ES1	NYDjeYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkn3TWM2OD1yLkGxNlU2KM7:TR?=	NUT1ZmN{W0GQR1XS
NCI-H1963	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrlbYJKSzVyPUCuNVE2PzlizszN	MU\TRW5ITVJ?
NCI-H1417	MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPWbW9UUUN3ME2wMlEzQTd2IN88US=>	NUHSTotVW0GQR1XS
NEC8	NIPQbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwMUO1Nlch\|ryP	MnvJV2FPT0WU
CRO-AP2	NYS0e2JxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zZN2lEPTB;MD6xOlg5QSEQvF2=	NH32cWlUSU6JRWK=
A3-KAW	NYf0U5V3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;VTWM2OD1yLkG3OlI4KM7:TR?=	NGHOWXBUSU6JRWK=
SF539	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHKUGhKSzVyPUCuNVk2QTNizszN	NGD6bIpUSU6JRWK=
NOS-1	M4\iNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWH4R\|NEUUN3ME2wMlE6PjF7IN88US=>	NWXB[lRLW0GQR1XS
NTERA-S-cl-D1	MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDBTWM2OD1yLkKwNVE{KM7:TR?=	NWPv[2tXW0GQR1XS
COR-L88	M4PSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzSTWM2OD1yLkKyPVU6KM7:TR?=	MX7TRW5ITVJ?
EM-2	NGXsXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7XTWM2OD1yLkK0NFc6KM7:TR?=	MYnTRW5ITVJ?
KARPAS-45	NILQXpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwMke4N\|Mh\|ryP	MnP0V2FPT0WU
DSH1	NHK4PWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LZcmlEPTB;MD6yPFcxQCEQvF2=	NV3zb4NXW0GQR1XS
HT-144	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTySlBkUUN3ME2wMlMxOjV4IN88US=>	MVTTRW5ITVJ?
ATN-1	NXLXZYRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjrbHFFUUN3ME2wMlMxPTd4IN88US=>	NEHRd4xUSU6JRWK=
HEL	NUPTOIRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mom1TWM2OD1yLkOxN\|Q5KM7:TR?=	NHnhRWZUSU6JRWK=
NB12	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoqzTWM2OD1yLkOxO\|U3KM7:TR?=	NVvFfYVTW0GQR1XS
LU-139	M3L0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfSTWM2OD1yLkOzOVEh\|ryP	NHj2TodUSU6JRWK=
J-RT3-T3-5	M1y2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwM{O3NVYh\|ryP	M2PpcHNCVkeHUh?=
MOLT-13	NWm0[Hl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTBwM{O4NUDPxE1?	M2nwWHNCVkeHUh?=
SR	NFjJNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnGTWM2OD1yLkO0NlYyKM7:TR?=	NGHuUW5USU6JRWK=
CMK	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnPfVk1UUN3ME2wMlM2PzJ5IN88US=>	NXfjVFF1W0GQR1XS
ES8	MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknYTWM2OD1yLkO2NFIzKM7:TR?=	NXjpclAyW0GQR1XS
LB647-SCLC	NEPuUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUCw[VZ2UUN3ME2wMlM3PzNizszN	MljzV2FPT0WU
TE-8	NF:xNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHzelRKSzVyPUCuN\|Y6OzVizszN	NX\DWWg5W0GQR1XS
BV-173	M3j6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLPNVJKSzVyPUCuN\|cyOjFizszN	NV20VIR5W0GQR1XS
DEL	NYjUS21pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4CwfmlEPTB;MD6zO\|Q5PyEQvF2=	NHLvb5RUSU6JRWK=
ARH-77	M{TOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwM{ixPVMh\|ryP	NFjwT\|dUSU6JRWK=
NCCIT	NH\sPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwM{i2OFkh\|ryP	M1[zenNCVkeHUh?=
RPMI-8402	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkX3TWM2OD1yLkO4O\|AyKM7:TR?=	MWrTRW5ITVJ?
MONO-MAC-6	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\IbmdKSzVyPUCuN\|g4PzZizszN	NGnubopUSU6JRWK=
SK-MM-2	NX3OU2hyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHrTWM2OD1yLkO5PFY5KM7:TR?=	MYXTRW5ITVJ?
CHP-126	NYfKSldjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXMbHJKSzVyPUCuOFAzOzFizszN	NUS3RYg6W0GQR1XS
A101D	NVLvdZY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HQXGlEPTB;MD60NFMh\|ryP	NGDpUopUSU6JRWK=
SCH	NWC0cXZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH20WXdKSzVyPUCuOFA{PDJizszN	NX;NdXFUW0GQR1XS
NMC-G1	M{XNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwNECzOlch\|ryP	MmP1V2FPT0WU
NCI-H209	NUDF[IIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzWTHhKSzVyPUCuOFA3OTNizszN	MmDOV2FPT0WU
MOLT-16	NEX3S3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DISGlEPTB;MD60NVAyPyEQvF2=	MoDKV2FPT0WU
RPMI-6666	NFjZ[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfsOZFKSzVyPUCuOFEyOiEQvF2=	MljsV2FPT0WU
OPM-2	NWSx[oZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVe1RWVVUUN3ME2wMlQyPTF\|IN88US=>	NXvPOGpUW0GQR1XS
MRK-nu-1	M17pZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwNEOxOVMh\|ryP	NF:2b4tUSU6JRWK=
BC-1	Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUiwb2dvUUN3ME2wMlQ{PDB\|IN88US=>	NYWwdXRQW0GQR1XS
MHH-NB-11	NXjINFFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LEXGlEPTB;MD60N\|Q2OyEQvF2=	NIH2foZUSU6JRWK=
Ramos-2G6-4C10	NV3zRmdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETuOHhKSzVyPUCuOFM5QTdizszN	NXzBXoZsW0GQR1XS
LS-513	NHS5epNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTBwNES1NFEh\|ryP	M1PmZXNCVkeHUh?=
K5	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fkUGlEPTB;MD60O\|AzPSEQvF2=	MonpV2FPT0WU
HOP-62	Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3QTWM2OD1yLkS4N\|U5KM7:TR?=	NF;uXI9USU6JRWK=
NCI-H187	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;oUnNSUUN3ME2wMlQ6OjJ5IN88US=>	NYTkbXNtW0GQR1XS
BE-13	MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnMc4ZKSzVyPUCuOFk3PjFizszN	M3HSSXNCVkeHUh?=
HC-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rPS2lEPTB;MD61NFQ4OyEQvF2=	MX3TRW5ITVJ?
ACN	NWq5fHhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwNUGwNlgh\|ryP	MWLTRW5ITVJ?
HCC1599	MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTBwNUG1O{DPxE1?	NF;SOnBUSU6JRWK=
MV-4-11	NHK4dYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3qwR2lEPTB;MD61N\|A1OSEQvF2=	MXPTRW5ITVJ?
LC-2-ad	MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwNUO2OlMh\|ryP	MY\TRW5ITVJ?
HL-60	M4fUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPmWIVKSzVyPUCuOVQzPjFizszN	NULZ[lRSW0GQR1XS
NB17	NGnQdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33uO2lEPTB;MD61OFM5KM7:TR?=	NHXuWWNUSU6JRWK=
TE-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfz[ZNCUUN3ME2wMlU2OzB4IN88US=>	M3HOU3NCVkeHUh?=
NCI-H524	NH7GdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17iVGlEPTB;MD61OVQxOSEQvF2=	NFHvU\|lUSU6JRWK=
MZ7-mel	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHxW2RKSzVyPUCuOVYyODVizszN	NHTLR4hUSU6JRWK=
L-363	NFjoPWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXwRnhKSzVyPUCuOVY3PTdizszN	M4rOW3NCVkeHUh?=
BL-41	NYe4ZoNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF70WlRKSzVyPUCuOVY5QDlizszN	MmnvV2FPT0WU
LU-134-A	M{\1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF31U4FKSzVyPUCuOVcxPzNizszN	MUXTRW5ITVJ?
SIG-M5	NFzTUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;UbYVKSzVyPUCuOVc5PDhizszN	MoKyV2FPT0WU
ONS-76	Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPCfVJLUUN3ME2wMlU5OjR{IN88US=>	NVLleGhDW0GQR1XS
KARPAS-299	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwNUi1NFQh\|ryP	Mn\YV2FPT0WU
DU-4475	NFfQeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXiSlBKSzVyPUCuOVg4ODNizszN	NX\DSYs1W0GQR1XS
NB69	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwNUm4NlUh\|ryP	NWC5U2lmW0GQR1XS
MHH-PREB-1	M2\5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvjUIxKSzVyPUCuOlA4OTlizszN	MXHTRW5ITVJ?
LU-165	NU\jeYMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwNkG4NVIh\|ryP	NF\GO\|NUSU6JRWK=
LOUCY	NXnuZmxnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwNkOzOlQh\|ryP	MmfCV2FPT0WU
NCI-H526	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;qZVUyUUN3ME2wMlY{PTRzIN88US=>	NGe2UYhUSU6JRWK=
KE-37	M{DTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFToT2VKSzVyPUCuOlQzPzZizszN	NWH6blR3W0GQR1XS
NALM-6	MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwNkS4OkDPxE1?	NWPiW\|RmW0GQR1XS
CW-2	NX2wemlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HGbGlEPTB;MD62OVc6PCEQvF2=	M{fZeHNCVkeHUh?=
SU-DHL-1	NETsZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwNkW5OFch\|ryP	Ml;sV2FPT0WU
NB13	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnO2TWM2OD1yLk[2PFE4KM7:TR?=	NWHXUm9IW0GQR1XS
QIMR-WIL	NGnudpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPWT5E5UUN3ME2wMlY5OzR\|IN88US=>	NVfWUJJEW0GQR1XS
ECC12	NH\DTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFX2eYRKSzVyPUCuO\|AxQDZizszN	MmfHV2FPT0WU
KALS-1	NVv1e2NYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGr3XldKSzVyPUCuO\|A1QTJizszN	MlfCV2FPT0WU
COR-L279	NXLJemVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTjUYNLUUN3ME2wMlcxQTl4IN88US=>	MlK3V2FPT0WU
NB14	Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3YTWM2OD1yLkeyOlE4KM7:TR?=	NGXENJhUSU6JRWK=
CCRF-CEM	NUTJbXF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwN{S2OlEh\|ryP	MXXTRW5ITVJ?
SW954	NWPkbHpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjkWotGUUN3ME2wMlc2QTl7IN88US=>	MXfTRW5ITVJ?
IST-SL1	NGXINZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3Kco1DUUN3ME2wMlc4OzR6IN88US=>	MXHTRW5ITVJ?
LAMA-84	NYfR[2x7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4m4V2lEPTB;MD63O\|U3PyEQvF2=	MoXJV2FPT0WU
Daudi	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PEUmlEPTB;MD63O\|Y5OSEQvF2=	NFPSPWtUSU6JRWK=
BC-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHhOGlKSzVyPUCuO\|g{ODhizszN	MYLTRW5ITVJ?
HCC2998	Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwN{izOkDPxE1?	NEPub5JUSU6JRWK=
NCI-H69	M1fPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXZTWM2OD1yLkiwNVQ4KM7:TR?=	NV7mdIp7W0GQR1XS
CPC-N	M1ezXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfvTWM2OD1yLkiwOVI1KM7:TR?=	M{LVUHNCVkeHUh?=
NOMO-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHLeFFKSzVyPUCuPFExQDRizszN	Ml;xV2FPT0WU
CESS	NX7uR4VzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlWzTWM2OD1yLkixNVk4KM7:TR?=	MWPTRW5ITVJ?
LC4-1	MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwOESwNFch\|ryP	NFv3dXJUSU6JRWK=
BL-70	M3KyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEP1RZJKSzVyPUCuPFU4ODJizszN	MoPvV2FPT0WU
ES4	MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPuSXpYUUN3ME2wMlg2QDZ6IN88US=>	MnXRV2FPT0WU
HCE-T	NGnxbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfPTWM2OD1yLki3NVcyKM7:TR?=	Mn3xV2FPT0WU
JAR	NEPRUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfWTWM2OD1yLki3PFI4KM7:TR?=	M{jHZ3NCVkeHUh?=
ST486	MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nHfGlEPTB;MD64O\|kyPyEQvF2=	NGXu[WVUSU6JRWK=
KS-1	NH;FfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkH2TWM2OD1yLki4NFk3KM7:TR?=	NEX6Zo9USU6JRWK=
GDM-1	Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYG4NXRZUUN3ME2wMlg5Pjh5IN88US=>	MmDEV2FPT0WU
EHEB	NIDEVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXlTWhKSzVyPUCuPVI2QDVizszN	NI[2Um1USU6JRWK=
LB2518-MEL	MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwOUOyPFQh\|ryP	MYXTRW5ITVJ?
GOTO	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTtTWM2OD1yLkm1NFc3KM7:TR?=	NH62SGlUSU6JRWK=
LXF-289	MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDyTWM2OD1yLkm1PVAyKM7:TR?=	MkDPV2FPT0WU
ES6	M3fJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwOU[0N\|ch\|ryP	M1e0OnNCVkeHUh?=
OS-RC-2	NHe4OWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\xNXpKSzVyPUCuPVY5OyEQvF2=	MlyxV2FPT0WU
DMS-153	NUGyZYVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfYXZlWUUN3ME2wMlk4PDZ7IN88US=>	NXT4cVZIW0GQR1XS
SK-PN-DW	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwOUe4N\|Eh\|ryP	M3fQTHNCVkeHUh?=
HH	MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFL4fI9KSzVyPUCuPVg6PTlizszN	MWfTRW5ITVJ?
SH-4	NF;HSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonBTWM2OD1zLkCyOFEh\|ryP	NXrzPYVmW0GQR1XS
MOLT-4	NXfJWnBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXoVZNMUUN3ME2xMlA{PDV2IN88US=>	MVTTRW5ITVJ?
TGW	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH2ySlVKSzVyPUGuNFc3PzVizszN	NEL0PJJUSU6JRWK=
L-540	MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH30fGVKSzVyPUGuNVA3ODRizszN	NVyzdW1ZW0GQR1XS
PF-382	NWfVeZNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPldlNKSzVyPUGuNVE2OTNizszN	NXPvZ3pCW0GQR1XS
LC-1F	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjDeYFYUUN3ME2xMlEzODB5IN88US=>	Ml\uV2FPT0WU
OVCAR-4	MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGP3OZJKSzVyPUGuNVMyPjVizszN	NWfrbYlvW0GQR1XS
A4-Fuk	Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4Cx[GlEPTB;MT6xOVM3PCEQvF2=	MXrTRW5ITVJ?
HCC2218	NWjtXoFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTFwMU[2OFEh\|ryP	M{nTUXNCVkeHUh?=
HAL-01	NVnHR4M{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{izfWlEPTB;MT6xOlk1OyEQvF2=	M1;Q[nNCVkeHUh?=
IST-MEL1	NVPzR4VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPiTWM2OD1zLkG3OlU6KM7:TR?=	NGLNVpZUSU6JRWK=
NCI-H719	NXrNWGtTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTFwMUe4PVgh\|ryP	NV:xd\|EyW0GQR1XS
EVSA-T	NWPUNmU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7vTWM2OD1zLkG4NVE1KM7:TR?=	MXLTRW5ITVJ?
SK-NEP-1	NX7yN5JbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIS3[4hKSzVyPUGuNlAzPjZizszN	MofhV2FPT0WU
OCUB-M	MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTFwMkG0PFkh\|ryP	MkDnV2FPT0WU
MEG-01	NYrsWXQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkixTWM2OD1zLkKyNVE5KM7:TR?=	NHWwdppUSU6JRWK=
no-10	MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTFwMkOxNVIh\|ryP	NXrXXW9YW0GQR1XS
MHH-CALL-2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHBXWtKSzVyPUGuNlQ4OjFizszN	NY\JdoNTW0GQR1XS
SK-N-DZ	MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTFwMkS3O\|Yh\|ryP	NEXxc4dUSU6JRWK=
SCLC-21H	MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVW3fYZ3UUN3ME2xMlI3PDd6IN88US=>	NFXtephUSU6JRWK=
CTV-1	NYDvPXZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDjZodKSzVyPUGuNlc1OjVizszN	M1jyXnNCVkeHUh?=
NB1	NV7Y[JpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXSVXNoUUN3ME2xMlI4PzN{IN88US=>	Mk\EV2FPT0WU
NCI-H64	MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3j4bmlEPTB;MT6yPFQ3OiEQvF2=	MVPTRW5ITVJ?
MDA-MB-134-VI	Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoS2TWM2OD1zLkK4OVc4KM7:TR?=	NHPUd2NUSU6JRWK=
LB2241-RCC	MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\hNoI{UUN3ME2xMlI5PjZ\|IN88US=>	NVS4dHQ6W0GQR1XS
8-MG-BA	NH;zXHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3PTWM2OD1zLkK4PFY3KM7:TR?=	NXy4N5R6W0GQR1XS
LP-1	NUDjV25ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DCUmlEPTB;MT6yPVk1PyEQvF2=	NVPIe5JMW0GQR1XS
LS-411N	NH3vbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTFwM{C5PVgh\|ryP	NH7xV5pUSU6JRWK=
CAL-148	NIXJWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M32wdGlEPTB;MT6zNlU1OiEQvF2=	NYDtSpVLW0GQR1XS
NCI-H2171	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTFwM{S1NFIh\|ryP	M4m0XnNCVkeHUh?=
JiyoyeP-2003	NF:2RVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTFwM{WzPUDPxE1?	MUDTRW5ITVJ?
NCI-H2107	NHizc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTFwM{W4PFMh\|ryP	MX7TRW5ITVJ?
BB30-HNC	NH7SU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HFRmlEPTB;MT6zPFk4QCEQvF2=	NXiyZoRFW0GQR1XS
K-562	NYPF[INHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnlTWM2OD1zLkO5NlE6KM7:TR?=	NWL3R2hQW0GQR1XS
PSN1	MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3u4PWlEPTB;MT60NlI5PyEQvF2=	MmLYV2FPT0WU
HCC2157	NFrye2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXz6NXVDUUN3ME2xMlQzPjlzIN88US=>	NUPPbWwxW0GQR1XS
SBC-1	NFjsVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HhemlEPTB;MT60Nlc1OSEQvF2=	MWDTRW5ITVJ?
MC116	M2TyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTFwNEO2NVUh\|ryP	M4TDWHNCVkeHUh?=
KARPAS-422	NUS0dVdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWn2e3pxUUN3ME2xMlQ2OzV6IN88US=>	NVH5VJMzW0GQR1XS
LB996-RCC	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTFwNEexNFMh\|ryP	MWXTRW5ITVJ?
MSTO-211H	NEPGSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnYUmFwUUN3ME2xMlQ4QTh5IN88US=>	MkT5V2FPT0WU
BT-474	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTYNI1KSzVyPUGuOVE4PjRizszN	M2q0XHNCVkeHUh?=
A388	NEi5VYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7EXZBKSzVyPUGuOVE6PDVizszN	NGTESJlUSU6JRWK=
SJSA-1	NWLuWJA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjxcHpKSzVyPUGuOVIzPiEQvF2=	MkXTV2FPT0WU
COLO-829	MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPVTWM2OD1zLkWzOVY1KM7:TR?=	NVfWc5pzW0GQR1XS
KM-H2	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTldFNrUUN3ME2xMlU3PjdizszN	NH\iWmNUSU6JRWK=
GR-ST	NILj[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTFwNU[4NkDPxE1?	M{W5WHNCVkeHUh?=
RPMI-8866	NFzEfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTFwNkCxOFQh\|ryP	NUnHTJdRW0GQR1XS
KG-1	NILkTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XnZ2lEPTB;MT62NVkxOSEQvF2=	MlTtV2FPT0WU
NCI-H82	NFy4U4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPFTWM2OD1zLk[zOFA3KM7:TR?=	NX7oSGJ7W0GQR1XS
LB1047-RCC	MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzITWM2OD1zLk[zOFU6KM7:TR?=	NU\CRnZbW0GQR1XS
KM12	NWTHXotCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn6yTWM2OD1zLk[0O{DPxE1?	NILDdYJUSU6JRWK=
NB5	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PEZmlEPTB;MT62OVY4PyEQvF2=	M13HUXNCVkeHUh?=
HDLM-2	MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHHUmNKSzVyPUGuOlgzQDFizszN	M1zVSXNCVkeHUh?=
KU812	MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXxTWM2OD1zLk[5OlA2KM7:TR?=	MVHTRW5ITVJ?
DB	M1PsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\O[W55UUN3ME2xMlcxOzV\|IN88US=>	NGrUSolUSU6JRWK=
HD-MY-Z	MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrBTWM2OD1zLke1NlM1KM7:TR?=	M2\ZSXNCVkeHUh?=
KURAMOCHI	Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTFwN{eyNFch\|ryP	MVPTRW5ITVJ?
ETK-1	NX21TYY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnf2TWM2OD1zLke4PFc6KM7:TR?=	M{nuVnNCVkeHUh?=
SK-UT-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;Rb5ZKSzVyPUGuO\|k{QDhizszN	NHTLPJpUSU6JRWK=
HUTU-80	MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;zVZJKSzVyPUGuO\|k2ODhizszN	NWToco9LW0GQR1XS
ES7	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTQfZRQUUN3ME2xMlgxOzB{IN88US=>	M12xdHNCVkeHUh?=
SW872	MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXSRmdKSzVyPUGuPFE{QTVizszN	NW\XZZJyW0GQR1XS
TK10	Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTFwOEOxNFgh\|ryP	M4DPZXNCVkeHUh?=
LB831-BLC	MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTWTWM2OD1zLkizOVY{KM7:TR?=	M3TucHNCVkeHUh?=
TE-9	NV7JU4VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fQTWlEPTB;MT64OFQzOiEQvF2=	M3rk[nNCVkeHUh?=
MLMA	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfZdGVKSzVyPUGuPFgzOzRizszN	MmjRV2FPT0WU
D-542MG	NFuzfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XzR2lEPTB;MT64PVM4OyEQvF2=	Ml2zV2FPT0WU
EW-16	Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XRTWlEPTB;MT65NlczKM7:TR?=	NHLOTZBUSU6JRWK=
LOXIMVI	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTFwOUOyPEDPxE1?	MlTSV2FPT0WU
GB-1	M4LMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHYcGNNUUN3ME2xMlk{QDZ4IN88US=>	Mk\BV2FPT0WU
IST-SL2	NYL1dppuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIexRY9KSzVyPUKuNFAzPjJizszN	NFrvPVlUSU6JRWK=
LAN-6	NGrROZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\3eHdOUUN3ME2yMlAyQTZ4IN88US=>	MWjTRW5ITVJ?
NCI-H510A	M4rXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFP4fXFKSzVyPUKuNFQ2ODJizszN	MWPTRW5ITVJ?
NCI-H1092	MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XwbmlEPTB;Mj6wOVEzPCEQvF2=	NV35e4dOW0GQR1XS
HT	NXvSS5VZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\KTWM2OD1{LkGwOFU1KM7:TR?=	MWTTRW5ITVJ?
RL95-2	M4S0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTJwMUG0PFIh\|ryP	M1f0VXNCVkeHUh?=
NCI-H1355	M3jWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vjTWlEPTB;Mj6xNVc6OiEQvF2=	Ml\XV2FPT0WU
NCI-H720	MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;2PIdQUUN3ME2yMlE3QDd\|IN88US=>	M2L1eXNCVkeHUh?=
NCI-H1522	NFPLW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDo[5FOUUN3ME2yMlIyPzJ\|IN88US=>	M1WwO3NCVkeHUh?=
LB373-MEL-D	M2\PZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX74SYdkUUN3ME2yMlI3QTB{IN88US=>	MnmxV2FPT0WU
DG-75	M2PaO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTJwMkexOFgh\|ryP	M{DCXXNCVkeHUh?=
ML-2	MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33XNmlEPTB;Mj6zNlg2PSEQvF2=	NXK3NINVW0GQR1XS
SF126	NHnnNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{CyO2lEPTB;Mj6zN\|A6PCEQvF2=	MoDOV2FPT0WU
MPP-89	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PaOWlEPTB;Mj6zN\|E1PSEQvF2=	M2nsbHNCVkeHUh?=
NCI-H345	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTJwM{OyO\|ch\|ryP	NIfjPZpUSU6JRWK=
LS-123	Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nhfmlEPTB;Mj6zOFk{PiEQvF2=	MoXBV2FPT0WU
NB10	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofNTWM2OD1{LkSxNFkzKM7:TR?=	NYjndmZzW0GQR1XS
CGTH-W-1	NHewdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnC[m5KSzVyPUKuOFIzPjdizszN	NHm0c3NUSU6JRWK=
CP66-MEL	MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonUTWM2OD1{LkS3O\|ch\|ryP	MX3TRW5ITVJ?
L-428	NGC2dIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HNcGlEPTB;Mj60PFUzOSEQvF2=	M2T2NnNCVkeHUh?=
DMS-79	M2iybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTJwNUSxNFMh\|ryP	M1nUPHNCVkeHUh?=
NCI-H1882	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDjUZZGUUN3ME2yMlY4PTZ{IN88US=>	NGfXV4dUSU6JRWK=
KGN	Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjmSJlFUUN3ME2yMlc3QDd4IN88US=>	MYrTRW5ITVJ?
EW-1	MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rifGlEPTB;Mj63O\|A5OyEQvF2=	MmLWV2FPT0WU
U-266	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnraTWM2OD1{Lki0PFI{KM7:TR?=	NVW3PYZSW0GQR1XS
COLO-320-HSR	M4\jbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTJwOEW2OFEh\|ryP	NEGwTWlUSU6JRWK=
KMOE-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vUdGlEPTB;Mj64O\|cyOSEQvF2=	NEHxW4FUSU6JRWK=
BB49-HNC	MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\ITWM2OD1{LkmyOFgh\|ryP	MlHrV2FPT0WU
GI-1	MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFP5NZJKSzVyPUKuPVI6PTdizszN	Mn7jV2FPT0WU
NCI-H1304	M3nr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzD[ZB[UUN3ME2zMlAxPTFzIN88US=>	NYT0VpE3W0GQR1XS
NCI-H2227	NGDMZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjMRXdKSzVyPUOuNFIxPzlizszN	MWTTRW5ITVJ?
U-87-MG	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnuTWM2OD1\|LkCzOVE{KM7:TR?=	NFrTdWFUSU6JRWK=
NCI-H747	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\pPZpKSzVyPUOuNFUzODZizszN	NV\FOXVrW0GQR1XS
CTB-1	M2TMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrDO\|hKSzVyPUOuNFU{PzZizszN	NXOzXnplW0GQR1XS
RPMI-8226	M3TJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjyVZZKSzVyPUOuNVQ{PzhizszN	NIfQSZlUSU6JRWK=
NCI-H2141	NGnJVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vndmlEPTB;Mz6xOlU3PiEQvF2=	NEnBOHBUSU6JRWK=
IST-MES1	NGnuOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkX4TWM2OD1\|LkG4Nlc6KM7:TR?=	M3n1WXNCVkeHUh?=
TE-5	NH[xTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4e0W2lEPTB;Mz6yNVM1OiEQvF2=	NFO1[pRUSU6JRWK=
UACC-257	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDxTWM2OD1\|LkSzOlU6KM7:TR?=	MnS4V2FPT0WU
SK-N-FI	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfucWxkUUN3ME2zMlQ2OjJ5IN88US=>	M4f2OnNCVkeHUh?=
MFH-ino	MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLQcpVKSzVyPUOuOFY2QDlizszN	MXzTRW5ITVJ?
SF268	NY\afIVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmC0TWM2OD1\|LkS4NVc1KM7:TR?=	M4jS[nNCVkeHUh?=
TE-12	M37wZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTNwNUG2PVkh\|ryP	MWTTRW5ITVJ?
NB6	NILubJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTNwNUW1OlMh\|ryP	NHLoOFVUSU6JRWK=
DJM-1	NWexc3dpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnmbFExUUN3ME2zMlU6QDl7IN88US=>	M{XyR3NCVkeHUh?=
MZ1-PC	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTNwNkG2NlQh\|ryP	NXzrNWtmW0GQR1XS
OCI-AML2	Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LJR2lEPTB;Mz62NlY4OSEQvF2=	Mo[0V2FPT0WU
NCI-H1155	M4fGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rzeGlEPTB;Mz63NFk1PyEQvF2=	NVPQSYFlW0GQR1XS
RKO	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHuTWM2OD1\|Lke3NVg6KM7:TR?=	Mn:3V2FPT0WU
ECC4	NWS1ZlBGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{flRmlEPTB;Mz65O\|E6PSEQvF2=	MmfGV2FPT0WU
BB65-RCC	MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLVTWM2OD1\|Lkm3OVQ4KM7:TR?=	NH[2VlRUSU6JRWK=
EB-3	NXXnNmRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTNwOUm2N\|Mh\|ryP	NH7xepJUSU6JRWK=
SHP-77	NYXmc4FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUW4S49wUUN3ME20MlAxPTJ2IN88US=>	Mli5V2FPT0WU
NCI-H2196	NFfHbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPxeHlKSzVyPUSuNFU3OjVizszN	NUXLUGJEW0GQR1XS
GI-ME-N	NGexNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF62OI5KSzVyPUSuNFY{QTlizszN	MoDIV2FPT0WU
MN-60	M4HBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPDTWM2OD12LkGwPFch\|ryP	NGDJbmlUSU6JRWK=
NCI-H1694	NHW2N4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfvflFKSzVyPUSuNVM1ODVizszN	MUXTRW5ITVJ?
LU-65	M1L4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTRwMUWzN\|Ih\|ryP	NYjIbZNzW0GQR1XS
NCI-H1436	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnEUpRKSzVyPUSuNVg{OzNizszN	M2G3TnNCVkeHUh?=
KINGS-1	MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoqxTWM2OD12LkOxOFMzKM7:TR?=	Mlm2V2FPT0WU
GT3TKB	NGS3eFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzITWM2OD12LkOzNlY5KM7:TR?=	NGn4e3BUSU6JRWK=
Becker	NVXWOmx5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUD2fmFtUUN3ME20MlM4OzF{IN88US=>	MVXTRW5ITVJ?
HCC1187	NX72TVZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHEN\|h5UUN3ME20Mlg6PjV5IN88US=>	M{i1PXNCVkeHUh?=
D-502MG	MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIK0O5pKSzVyPUWuNFA1OTZizszN	MkDLV2FPT0WU
VA-ES-BJ	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TReWlEPTB;NT6xN\|c4QCEQvF2=	M4TUcXNCVkeHUh?=
NB7	NF;ydFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LufmlEPTB;NT6xOFEyOiEQvF2=	M2r2bXNCVkeHUh?=
SW962	M1OyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTVwM{i4NVQh\|ryP	M2TDRnNCVkeHUh?=
no-11	NVjuOWNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fNbmlEPTB;NT63OlM1OyEQvF2=	M3;QdXNCVkeHUh?=
KNS-81-FD	MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;Wd2hnUUN3ME21MlkxPjl2IN88US=>	MkPtV2FPT0WU
COLO-684	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4S4UGlEPTB;NT65PVQ6PCEQvF2=	NWfRVFRMW0GQR1XS
D-263MG	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoG1TWM2OD14LkC4PFk2KM7:TR?=	NX2wdml5W0GQR1XS
EW-24	M1jCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPETWM2OD14LkK4OVEh\|ryP	M3jCWnNCVkeHUh?=
TE-10	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rCXWlEPTB;Nj60NlYzOyEQvF2=	MkTiV2FPT0WU
EKVX	NUPzV2JmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1v0d2lEPTB;Nj60OlMzOSEQvF2=	MoTuV2FPT0WU
NCI-H1648	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTZwNke1OVch\|ryP	NYTRcHg2W0GQR1XS
LB771-HNC	M{PacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH[2bJpKSzVyPU[uPVI{ODFizszN	MoTXV2FPT0WU
SK-MEL-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrkTWM2OD16LkGzNVY3KM7:TR?=	NYjqbVdHW0GQR1XS
COLO-668	NUi2XlhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHlTWM2OD16LkK3O\|g3KM7:TR?=	MnXFV2FPT0WU
EW-12	NGTFWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRThwNEC4NFMh\|ryP	MonzV2FPT0WU
A253	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW[3NJNoUUN3ME24Mlg1PjZzIN88US=>	M3f3WHNCVkeHUh?=
NCI-H2126	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jaeGlEPTB;OD64PVMyQSEQvF2=	MmnRV2FPT0WU
Calu-6	NIn6[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PDe2lEPTB;OD65PVA1OiEQvF2=	M1WxeHNCVkeHUh?=
NCI-H23	M2XqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnWTWM2OD17LkG3O\|Q3KM7:TR?=	M3PLU3NCVkeHUh?=
WSU-NHL	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{SyV2lEPTB;OT63O\|Q4QCEQvF2=	MkfQV2FPT0WU
MMAC-SF	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvUTWM2OD17Lkm3PVA1KM7:TR?=	NV;zfHJbW0GQR1XS
SK-LMS-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDSWHY5UUN3ME2xNE4zQDN2IN88US=>	MoH0V2FPT0WU
GCIY	MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzid5FUUUN3ME2xNE42QTJ2IN88US=>	NYrnWZN5W0GQR1XS
TE-15	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTFzLk[wNFQh\|ryP	NXOwcIVmW0GQR1XS
EoL-1-cell	M3rBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTFzLke2PFIh\|ryP	M4TJWXNCVkeHUh?=
NCI-H2081	NXH6WINsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHDTWM2OD1zMT63O\|g3KM7:TR?=	Mkf2V2FPT0WU
EW-3	M2\pTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTF{LkK0OlMh\|ryP	MnfyV2FPT0WU
CAS-1	NHnTe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU[wblg3UUN3ME2xNk4{PjNzIN88US=>	NH\Be5BUSU6JRWK=
C2BBe1	NF\TboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYW2Z2g3UUN3ME2xNk43OTNzIN88US=>	NVnlT446W0GQR1XS
D-247MG	MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHWTWM2OD1zMj63PVUzKM7:TR?=	NF:zToxUSU6JRWK=
NCI-SNU-5	NV7iN\|hRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPHTpBGUUN3ME2xNk45ODF\|IN88US=>	MWrTRW5ITVJ?
LS-1034	NF\FeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTF2LkO5O\|Uh\|ryP	NUGydlI6W0GQR1XS
EW-18	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoK3TWM2OD1zND60OFgh\|ryP	MnGyV2FPT0WU
Raji	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHWNm9LUUN3ME2xOE42ODR7IN88US=>	Mn;hV2FPT0WU
D-283MED	MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDMTWM2OD1zND62NlcyKM7:TR?=	NX\PfYFPW0GQR1XS
MZ2-MEL	NGr6S29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjnTWM2OD1zND65Olk3KM7:TR?=	M13tfXNCVkeHUh?=
NCI-SNU-16	M120VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrycoJKSzVyPUG1MlQ3OzNizszN	NGW3SIRUSU6JRWK=
P30-OHK	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLRTWM2OD1zNz63PFMyKM7:TR?=	NX3Dd5Z7W0GQR1XS
RXF393	Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfNNmFXUUN3ME2xPU4xOTh4IN88US=>	M3nYT3NCVkeHUh?=
NCI-H1395	NELKPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHlSVBKSzVyPUKwMlY4ODNizszN	MYHTRW5ITVJ?
U-698-M	M{HBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPURotsUUN3ME2yNE44ODd3IN88US=>	MmnWV2FPT0WU
NCI-SNU-1	M17aRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\4cI41UUN3ME2yNE44OjJ\|IN88US=>	MV3TRW5ITVJ?
SW684	NFzJ[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjN[ldKSzVyPUKxMlE4OTZizszN	M1fyR3NCVkeHUh?=
NCI-H716	M4m4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTiTWM2OD1{MT6zNVU1KM7:TR?=	NXXJTZF6W0GQR1XS
JVM-2	NFG5N5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfTRlhIUUN3ME2yNU41OTN\|IN88US=>	NX;nR3hNW0GQR1XS
NCI-H1581	NWrkc4RqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTJ{LkSxOFgh\|ryP	M1\yN3NCVkeHUh?=
CA46	NUXFfWtDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfnS\|hKSzVyPUOxMlY6OzZizszN	MnLCV2FPT0WU
SNB75	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHMTWM2OD1\|Mz62OVA{KM7:TR?=	MVnTRW5ITVJ?
KNS-42	NEX3dpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DQPGlEPTB;M{WuPVYzPCEQvF2=	NEnDVW5USU6JRWK=
TUR	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzoeG9KSzVyPUO2MlA2OjFizszN	MXTTRW5ITVJ?
REH	M1:4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTN5LkiyNVEh\|ryP	MYrTRW5ITVJ?
EW-22	Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jNb2lEPTB;NEKuNlg5PSEQvF2=	MYnTRW5ITVJ?
NCI-H446	NYnUdFNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWP4bXB1UUN3ME20Nk44QDV\|IN88US=>	NXK3SmFpW0GQR1XS
ES3	M1\abGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTR\|LkGzN\|kh\|ryP	MmG3V2FPT0WU
EW-11	NX\XWotsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTR2LkiyNVgh\|ryP	MXnTRW5ITVJ?
RH-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUm4e5dPUUN3ME20O{42QDF{IN88US=>	NIHuN5JUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; PubMed: 24203492 Pharm Res HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. Cleaved PARP; PubMed: 19148581 J Neurooncol Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control. Caspase 8 ; PubMed: 19148581 J Neurooncol Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression. DR4 / DR5; PubMed: 19148581 J Neurooncol Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h. TopoIIα / TopoIIβ; PubMed: 21254166 Hepatology Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.	24203492 19148581 21254166
Immunofluorescence	phalloidin / snail; PubMed: 29855565 Sci Rep (C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed. DR4 / DR5; PubMed: 19148581 J Neurooncol Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls. H3K4Me3 / H3K9Me3; PubMed: 22468166 Mol Cell Pharmacol Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.	29855565 19148581 22468166
Growth inhibition assay	Cell proliferation; PubMed: 24203492 Pharm Res (A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. , P < 0.05, ; P ≤ 0.01; **, P ≤ 0.001 Cell viability; PubMed: 28969017 Oncotarget PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.	24203492 28969017
ELISA	GCP-2 / MCP-2 / MIF ; PubMed: 24241152 Molecules MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).	24241152

In vivo

MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. ^[1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. ^[4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. ^[5]

Protocol

Kinase Assay: ^[6]	- Collapse Standard HDAC Assays: Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λ_ex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. K_m and V_max values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research: ^[2]	- Collapse Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells Concentrations: ~ 10 μM Incubation Time: 3 days Method: Cancer cells (5 × 10³) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO₂-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na₂HPO₄ is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice. Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80 Dosages: 12.3, 24.5 and 49 mg/kg Administration: Administered orally once daily 5 days per week for 4 weeks (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	75 mg/mL (199.25 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Entinostat (MS-275) SDF

Molecular Weight	376.41
Formula	C₂₁H₂₀N₄O₃
CAS No.	209783-80-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SNDX-275

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03829930	Recruiting	Drug: Entinostat\|Drug: Enzalutamide	Prostate Adenocarcinoma	George Washington University	May 1 2019	Phase 1
NCT03765229	Recruiting	Drug: Entinostat\|Drug: Pembrolizumab	Melanoma	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals Inc.	March 22 2019	Phase 2
NCT03473639	Recruiting	Drug: Entinostat\|Drug: Capecitabine	Metastatic Breast Cancer\|Breast Cancer	University of Virginia\|Syndax Pharmaceuticals	January 29 2019	Phase 1
NCT03361800	Recruiting	Drug: Entinostat	Breast Cancer\|Invasive Breast Cancer\|ER-Negative PR-Negative HER2-Negative Breast Cancer	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals\|National Cancer Institute (NCI)	November 28 2018	Early Phase 1
NCT03192111	Completed	Drug: Entinostat	Renal Impairment\|Healthy Volunteer	Syndax Pharmaceuticals	July 27 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to use Entinostat（Catalog No.S1053） for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?
Answer:
2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202,Domatinostat) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Vorinostat (SAHA, MK0683)

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Entinostat (MS-275)

Cited by 271 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Entinostat (MS-275) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Choose Your Country or Region

By Signaling Pathways

By product type

Entinostat (MS-275)

Cited by 271 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Entinostat (MS-275) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)